Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.81 USD | -3.34% | -22.34% | -20.32% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- Low profitability weakens the company.
- The company is in debt and has limited leeway for investment
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-20.32% | 2.49B | - | ||
+33.37% | 50.85B | B- | ||
+1.55% | 42.82B | B | ||
+49.11% | 42.03B | A | ||
-4.22% | 29.55B | C | ||
+11.57% | 26.11B | B- | ||
-21.00% | 19.13B | B | ||
+7.36% | 13.05B | B+ | ||
+28.30% | 12.16B | C+ | ||
+23.80% | 12.08B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- FTRE Stock
- Ratings Fortrea Holdings Inc.